Business
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
First patient in South Korea dosedMIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today announced activation of two South Korean clinical trial sites participating in its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PAS-004, in adult participants with neurofi
About this update from Asana, Inc.
[{"type":"image","alt":"Pasithea","displaySize":"","headline":null,"caption":"Pasithea","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":143,"url":"https://media.zenfs.com/en/globenewswire.com/d11ee27698b4a1476f1edcbf6394a4a6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ttBUffdOjF6_VI2FNlMsxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d11ee27698b4a1476f1edcbf6394a4a6","width":300,"height":143}},"lazy":false},{"type":"text","content":"First patient in South Korea dosed","length":34,"tagName":"p"},{"type":"text","content":"MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor today announced activation of two South Korean clinical trial sites participating in its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PAS-004, in adult participants with neurofibromatosis type 1 (NF1) with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas.","length":583,"tagName":"p"},{"type":"text","content":"The South Korea clinical trial sites, ASAN Medical Centre and Severance Hospital Yonsei University Health System, are now actively recruiting NF1 trial participants.","length":165,"tagName":"p"},{"type":"text","content":"Professor Lee Beom-Hee of the Department of Pediatrics at Asan Medical Center said, “I am very pleased to partner with the Pasithea team to initiate testing of PAS-004 in adult patients with plexiform neurofibromas associated with NF1 at Asan Medical Center. Our institution has the largest NF1 caseload in South Korea and a long history of research leadership in this field. Our team was among the first to report the therapeutic benefits of MEK inhibition on neurocognitive decline, café-au-lait spots, and growth retardation caused by neurofibromatosis. We are eager to evaluate PAS-004, a next-generation MEK inhibitor that to date has demonstrated a distinct pharmacokinetic profile and a more convenient dosing regimen, which we believe may provide important benefits for our NF1 patients.”","length":796,"tagName":"p"},{"type":"text","content":"Dr. Tiago Reis Marques, chief executive officer of Pasithea c...